Enzo Biochem

These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates through three segments: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers around the world. Enzo Clinical Labs segment provides diagnostic services to the healthcare community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.
Company Growth (employees)
New York, US
Size (employees)
446 (est)
Enzo Biochem was founded in 1976 and is headquartered in New York, US

Enzo Biochem Office Locations

Enzo Biochem has an office in New York
New York, US (HQ)
527 Madison Ave

Enzo Biochem Metrics

Enzo Biochem Financial Metrics

Revenue (2016)

$102.8 m

Revenue growth (2015-16), %


Net income (2016)

$45.3 m

Market capitalization (21-Mar-2017)

$363.4 m

Closing share price (21-Mar-2017)


Cash (31-Jul-2016)

$67.8 m
Enzo Biochem's current market capitalization is $363.4 m.
Enzo Biochem's revenue was reported to be $102.8 m in FY, 2016 which is a 5.3% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$93.7 m$95.9 m$97.6 m$102.8 m

Revenue growth, %


Operating expense total

$112.7 m$106.1 m$98.8 m$55.8 m


($19 m)($10.2 m)($1.2 m)$47 m

EBIT margin, %


Interest expense

$54 k$208 k$245 k$136 k

Pre tax profit

($18.9 m)($9.9 m)($2.3 m)$46.5 m

Income tax expense

($712 k)$72 k($7 k)$1.2 m

Net Income

($18.2 m)($10 m)($2.3 m)$45.3 m
FY, 2013FY, 2014FY, 2015FY, 2016


$9 m$17.5 m$18.1 m$67.8 m

Accounts Receivable

$6.7 m$6.7 m


$8.8 m$8.7 m$7.4 m$7 m

Current Assets

$32.6 m$40.7 m$46.5 m$91.4 m


$8.6 m$7.7 m$7.9 m$8.2 m


$7.5 m$7.5 m$7.5 m$7.5 m

Total Assets

$59 m$64.4 m$68.4 m$111.8 m

Accounts Payable

Current Liabilities

$23.9 m$25 m$24 m$20.6 m

Additional Paid-in Capital

$304.3 m$317.2 m$325 m$326.3 m

Retained Earnings

($272.4 m)($282.4 m)($284.7 m)($239.4 m)

Total Equity

$42.6 m$89.6 m

Financial Leverage

1.6 x1.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($18.2 m)($10 m)($2.3 m)$45.3 m

Accounts Receivable

($2.6 m)($3.2 m)($2 m)($4.8 m)


$60 k$159 k$1.2 m$466 k

Accounts Payable

Cash From Operating Activities

($10 m)($1.7 m)($3.7 m)$53.1 m

Capital Expenditures

($988 k)($838 k)($1.8 m)($1.5 m)

Cash From Investing Activities

($971 k)($833 k)($1.8 m)($1.5 m)

Cash From Financing Activities

$10.9 m$6.2 m($1.9 m)

Free Cash Flow

($9 m)($859 k)($1.9 m)$54.7 m

Enzo Biochem Operating Metrics

FY, 2016

Patents Issued


Patents Pending




Enzo Biochem Market Value History

Enzo Biochem Revenue Breakdown

Enzo Biochem Company Life

You may also be interested in